NF-κB activation mediates resistance to IFNΒ in MLL-rearranged acute lymphoblastic leukemia

Leukemia

Volumn 24, Issue 4, 2010, Pages 806-812

  Tracey, L ^a   Streck, C J ^a   Du, Z ^b   Williams, R F ^a   Pfeffer, L M ^b   Nathwani, A C ^c   Davidoff, A M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

11) translocation; Acute lymphoblastic leukemia; Interferon beta (IFN ); Nuclear factor kappa B (NF B); T(4

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MIXED LINEAGE LEUKEMIA PROTEIN; PARVOVIRUS VECTOR; RECOMBINANT BETA INTERFERON; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; ANTINEOPLASTIC AGENT; BETA INTERFERON; MESSENGER RNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER MODEL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 4; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE ACTIVATION; GENE EXPRESSION; GENE REARRANGEMENT; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; ANIMAL; CELL PROLIFERATION; CHROMOSOME 11; CHROMOSOME 4; DRUG EFFECT; DRUG SCREENING; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 4; DEPENDOVIRUS; DRUG RESISTANCE, NEOPLASM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; HUMANS; INTERFERON-BETA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICE, SCID; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSLOCATION, GENETIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950930700     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.2     Document Type: Article

References (31)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol 2004; 83 (Suppl 1): S124-S126.
3. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR et al. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996; 87: 2870-2877.
4. Pui CH, Behm FG, Downing JR, Hancock ML, Shurtleff SA, Ribeiro RC et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12: 909-915.
5. Pui CH, Chessells JM, Camitta B, Baruchel A, Biondi A, Boyett JM et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706.
6. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909-1915.
7. Benjamin R, Khwaja A, Singh N, McIntosh J, Meager A, Wadhwa M et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 2007; 109: 1244-1247.
8. Streck CJ, Dickson PV, Ng CY, Zhou J, Hall MM, Gray JT et al. Antitumor efficacy of AAV-mediated systemic delivery of inter-feron-beta. Cancer Gene Ther 2006; 13: 99-106.
9. Streck CJ, Zhang Y, Miyamoto R, Zhou J, Ng CY, Nathwani AC et al. Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta. Surgery 2004; 136: 183-189.
10. Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, Trautmann U et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 1994; 86: 275-283.
11. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC, Kersey JH. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21-31.
12. Yang CH, Murti A, Pfeffer SR, Basu L, Kim JG, Pfeffer LM. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci USA 2000; 97: 13631-13636.
13. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005; 11: 875-888.
14. Baranzini SE, Mousavi P, Rio J, Caillier SJ, Stillman A, Villoslada P et al. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 2005; 3: e2.
15. Shang D, Liu Y, Ito N, Kamoto T, Ogawa O. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci 2007; 98: 1259-1264.
16. Sun WH, Pabon C, Alsayed Y, Huang PP, Jandeska S, Uddin S et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998; 91: 570-576.
17. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997; 272: 28779-28785.
18. Yang CH, Murti A, Pfeffer LM. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci USA 1998; 95: 5568-5572.
19. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22: 304-311.
20. Abramovich C, Shulman LM, Ratovitski E, Harroch S, Tovey M, Eid P et al. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta. EMBO J 1994; 13: 5871-5877.
21. Brinckmann A, Axer S, Jakschies D, Dallmann I, Grosse J, Patzelt T et al. Interferon-alpha resistance in renal carcinoma cells is associated with defective induction of signal transducer and activator of transcription 1 which can be restored by a supernatant of phorbol 12-myristate 13-acetate stimulated peripheral blood mononuclear cells. Br J Cancer 2002; 86: 449-455.
22. Zitzmann K, Brand S, De Toni EN, Baehs S, Goke B, Meinecke J et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 2007; 67: 5025-5032.
23. Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ. Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther 2008; 7: 1827-1835.
24. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006; 20: 61-67.
25. Hewamana S, Lin TT, Jenkins C, Burnett AK, Jordan CT, Fegan C et al. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res 2008; 14: 8102-8111.
26. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 2007; 67: 3853-3861.
27. Mi J, Zhang X, Rabbani ZN, Liu Y, Reddy SK, Su Z et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008; 16: 66-73.
28. Sors A, Jean-Louis F, Begue E, Parmentier L, Dubertret L, Dreano M et al. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res 2008; 14: 901-911.
29. Tracey L, Spiteri I, Ortiz P, Lawler M, Piris MA, Villuendas R. Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. J Interferon Cytokine Res 2004; 24: 185-195.
30. Wozniak MB, Tracey L, Ortiz-Romero PL, Montes S, Alvarez M, Fraga J et al. Psoralen plus ultraviolet A +/\interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. BrJ Dermatol 2009; 160: 92-102.
31. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 2001; 276: 13756-13761.